CAMP4 Therapeutics Corporation (CAMP) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2023
Revenue
Total Revenue	4.2M	3.5M	652.0K	350.0K	294.9M
Cost of Revenue	936.0K	1.6M	—	—	185.9M
Gross Profit	3.3M	1.9M	652.0K	350.0K	109.0M
Operating Expenses
R&D Expense	38.2M	38.2M	38.8M	40.6M	24.6M
SG&A Expense	17.9M	17.4M	14.9M	11.6M	99.2M
General & Admin Expense	17.9M	17.4M	14.9M	11.6M	51.8M
Selling & Marketing Expense	—	—	—	—	47.4M
Other Expenses	(416.0K)	(1.6M)	—	—	9.9M
Total Operating Expenses	55.7M	53.9M	53.7M	52.2M	133.7M
Cost and Expenses	56.6M	55.6M	53.7M	52.2M	319.6M
Operating Income (EBIT)	(52.4M)	(52.1M)	(53.1M)	(51.9M)	(24.7M)
Non-Operating
Interest Income	2.9M	2.2M	1.3M	2.8M	989.0K
Interest Expense	—	—	—	—	6.3M
Net Interest Income	2.9M	2.2M	1.3M	2.8M	(5.3M)
Other Non-Op Income/Expense	(54.9M)	(28.3M)	1.3M	2.6M	(6.7M)
Non-Operating Income (excl Interest)	22.1M	—	—	—	394.0K
EBT (Pre-Tax Income)	(107.2M)	(80.4M)	(51.8M)	(49.3M)	(31.3M)
Income Tax Expense	—	—	—	—	1.2M
Bottom Line
Net Income	(107.2M)	(80.4M)	(51.8M)	(49.3M)	(32.5M)
Earnings from Cont. Ops	(107.2M)	(80.4M)	(51.8M)	(49.3M)	(32.5M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(107.2M)	(80.4M)	(51.8M)	(49.3M)	(32.5M)
Per Share
Basic EPS	($2.23)	($2.65)	($2.66)	($4.07)	($0.90)
Diluted EPS	($2.23)	($2.65)	($2.66)	($4.07)	($0.90)
Revenue Per Share	$0.07	$0.12	$0.03	$0.03	$8.16
Shares
Basic Shares Outstanding	57.9M	30.4M	19.5M	12.1M	36.1M
Diluted Shares Outstanding	57.9M	30.4M	19.5M	12.1M	36.1M
Profitability Metrics
EBITDA	(73.2M)	(50.4M)	(51.4M)	(50.2M)	(25.1M)
D&A	1.3M	1.6M	1.7M	1.7M	—
EBIT	(74.5M)	(52.1M)	(53.1M)	(51.9M)	(25.1M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026